MedPath
HSA Approval

ABIRATERONE-TEVA FC TABLET 500 MG

SIN16987P

ABIRATERONE-TEVA FC TABLET 500 MG

ABIRATERONE-TEVA FC TABLET 500 MG

April 18, 2024

TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantTEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

TABLET, FILM COATED

ORAL

Medical Information

L02BX03

abiraterone

Manufacturer Information

TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.

TEVA Pharmaceutical Industries, Ltd.

Active Ingredients

Abiraterone acetate

500 mg

Abiraterone

Documents

Package Inserts

Abiraterone-Teva Film Coated Tablet PI.pdf

Approved: April 18, 2024

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

ABIRATERONE-TEVA FC TABLET 500 MG - HSA Approval | MedPath